Abstract:Background: Osteosarcoma (OS) is the most common primary malignant bone tumor in children and adolescents, known for its aggressive nature and high potential for metastasis. Despite standard of care, the 5-year survival rate in OS patients remains at 60%-70%, with the primary cause of death being metastatic disease. Histotripsy, an emerging non-invasive, non-thermal, and non-ionizing ablation technique, uses high- intensity focused ultrasound to mechanically destroy tumor tissues. This process can release damage-associated molecular patterns (DAMPs) and tumor antigens, which may stimulate an anti-tumor immune response. N-dihydrogalactochitosan (GC) is a novel immunostimulant previously reported to enhance systemic immune responses when administered intratumorally following local thermal tumor ablation. However, the combination of GC with a non-thermal ablation modality such as histotripsy remains unexplored. This study aimed to investigate the safety and feasibility of combining histotripsy and GC as a novel treatment modality to induce immunomodulation, which is crucial for mitigating metastatic disease. Methods: The syngeneic C3H/HeN mouse model with the DLM8 OS cell line was utilized for this study. Bilateral subcutaneous flank tumors were inoculated into the mice, with one tumor treated with histotripsy and GC, while the contralateral tumor was left untreated. Histotripsy was performed using a 1 MHz histotripsy transducer with 1-2 cycle pulses, a pulse repetition frequency (PRF) of 250 Hz, and 500 pulses per point. GC was administered intratumorally at a dose of 10 mg/mL, determined through a preliminary pilot study to ensure optimal immune response activation without adverse effects. Tumor growth in both treated and contralateral tumors was monitored. At 7-10 days post treatment the local tumor immune response was evaluated through histological analysis for overall immune cell infiltration and flow cytometry for immunophenotyping of T cells, dendritic cells and macrophages. Control groups included bilateral tumor-bearing mice treated with histotripsy only, GC only, or left untreated to evaluate the outcomes of histotripsy + GC treatment. Results: Initial data indicate that the combination of histotripsy and GC led to stabilization of tumor growth in both treated and contralateral tumors within the 7–10- day post-treatment observation period. In contrast, tumors in the control groups exhibited 80%-100% increase in their largest diameter during the same timeframe. We observed increased infiltration of neutrophils, eosinophils, and macrophages in the treated tumors of the combination group compared to the control groups, indicating robust local immune activation. Conclusion: Our preliminary findings suggest that combining histotripsy with GC may offer a therapeutic strategy for OS by stabilizing tumor growth and enhancing immune cell infiltration in the tumor microenvironment. Future directions will include long-term evaluations to assess the sustained efficacy and potential systemic immune responses induced by the combination therapy. Citation Format: Ny T.C. Luong, Elliana R Vickers, Alayna Hay, Sheryl L Coutermarsh-Ott, Samuel S.K. Lam, Wei R Chen, Eli Vlaisavljevich, Joanne Tuohy. Investigating the immunomodulatory effects of combined histotripsy and N-dihydrogalactochitosan: A novel non-invasive therapeutic strategy for osteosarcoma [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr B020.

Abstract B021: A preclinical murine model investigation; Focused ultrasound ablation of osteosarcoma induces local and systemic immunomodulation

Abstract B020: Investigating the immunomodulatory effects of combined histotripsy and N-dihydrogalactochitosan: A novel non-invasive therapeutic strategy for osteosarcoma.

Spatiotemporal local and abscopal cell death and immune responses to histotripsy focused ultrasound tumor ablation

Abstract 2665: Immune cell modulation of pulsed focused ultrasound in murine melanoma and breast cancer models

Abstract 4069: IL12-expressing genetically engineered myeloid cells remodel the stromal dense and T cell poor tumor microenvironment and premetastatic niche of F42010 murine osteosarcoma

Abstract 4201: Immune priming with low intensity focused ultrasound and radiation therapy in murine breast cancer

Abstract 5461: Antecedent STING agonist therapy improves tumor response to chemotherapy in murine models of osteosarcoma

Abstract B032: Novel immunotherapy approach for metastatic triple-negative breast cancer

Abstract 1087: Synergistic mechanisms against pediatric bone sarcoma models: Trabectedin enhances oncolytic virotherapy intratumoral spread and antitumor immune activation

Abstract 709: Enhancing prostate cancer treatment: Synergistic effects of mechano-thermal focused ultrasound and radiation therapy

Abstract 6336: Unleashing CAR T cell activity against osteosarcoma using tumor specific RNA-based vaccination

Abstract 6642: Exploring the x-ray psoralen activated cancer therapy mechanism of action in a genetically engineered mouse model of soft tissue sarcoma

Abstract 1668: Development and characterization of a c-Myc-driven preclinical mouse model of osteosarcoma to investigate the tumor immune microenvironment

Histotripsy ablation stimulates the innate immune system and modulates anti-tumor immunity in pancreatic cancer

Abstract 4033: Leukocyte-based biomimetic nanoparticles for combined targeted and immunotherapy in osteosarcoma

Abstract 1083: Cell membrane-anchored and tumor-targeted IL12 T-cell therapy destroys cancer-associated fibroblasts and disrupts extracellular matrix in heterogenous osteosarcoma xenograft models

Abstract B024: A histological data-driven analysis of the hypoxic microenvironment of preclinical murine bladder tumors

The use of histotripsy as intratumoral immunotherapy beyond tissue ablation-the rationale for exploring the immune effects of histotripsy

Abstract 6833: Microenvironment-specific transcriptomic changes in osteosarcoma metastasis

Abstract 4204: Subcutaneous vs. orthotopic tumor models: A comparative assessment

Abstract 1456: First successful engraftment of human liver cancer cell line in highly robust immunocompromised porcine model to test the tumor ablation efficacy by histotripsy